



NDA 17-498/S-029

Pharmacia & Upjohn Company
Attention: Kathleen Collins
Manager, Worldwide Regulatory Strategy
235 East 42nd Street
New York, NY 10017

Dear Ms. Collins:

Please refer to your supplemental new drug application dated March 4, 2009, received March 4, 2009, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Micronase (glyburide) Tablets.

We acknowledge receipt of your submission dated April 9, 2009.

This "Changes Being Effected" supplemental new drug application provides for the addition of language regarding Hemolytic Anemia under the PRECAUTIONS section of the Package Insert. This supplement was submitted in response to our supplement request letter dated January 15, 2009.

We have completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format as described at <http://www.fda.gov/oc/datacouncil/spl.html> that is identical in content to the enclosed labeling (text for package insert submitted on April 9, 2009). Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission, "SPL for approved NDA 17-498/S-029."

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
Suite 12B05
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

NDA 17-498/S-029

Page 2

If you have any questions, call Julie Marchick, Regulatory Project Manager, at (301) 796-1280.

Sincerely,

{See appended electronic signature page}

Mary H. Parks, M.D.
Director
Division of Metabolism and Endocrinology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure: Package Insert

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MARY H PARKS

08/27/2009